Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Drops By 13.6%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 24,100 shares, a decline of 13.6% from the February 13th total of 27,900 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average trading volume of 13,300 shares, the short-interest ratio is currently 1.8 days.

Wall Street Analysts Forecast Growth

VTVT has been the subject of a number of research reports. Alliance Global Partners started coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company. StockNews.com assumed coverage on vTv Therapeutics in a report on Wednesday. They set a “sell” rating for the company.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC bought a new position in shares of vTv Therapeutics in the third quarter worth $2,402,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in vTv Therapeutics during the 4th quarter valued at about $25,000. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $17.60 on Friday. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $30.99. The business has a 50-day moving average of $16.92 and a 200 day moving average of $15.44. The firm has a market cap of $56.14 million, a P/E ratio of -3.89 and a beta of 1.07.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million during the quarter.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.